{"id":"https://genegraph.clinicalgenome.org/r/f33b00b8-81c5-4fa5-af66-2ca43b3b4995v1.0","type":"EvidenceStrengthAssertion","dc:description":"","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/f33b00b8-81c5-4fa5-af66-2ca43b3b4995","GCISnapshot":"https://genegraph.clinicalgenome.org/r/0063ff66-c988-4635-a309-2af473917898","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/0063ff66-c988-4635-a309-2af473917898_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2018-06-14T14:54:01.804Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/0063ff66-c988-4635-a309-2af473917898_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2020-09-01T00:00:00Z","role":"Publisher"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0063ff66-c988-4635-a309-2af473917898_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0063ff66-c988-4635-a309-2af473917898_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/51eee91f-6c20-4fd3-9548-d85c295577b2","type":"EvidenceLine","dc:description":"The procedure by which the variant was ultimately expressed in this mouse does not truly recapitulate the situation in a human patient (the variant was not on the mouse homolog of KCNQ2, it was expressed on the X-chromosome and displayed sex-limited expression, etc.). Because of these issues, the EIEE gene curation working group has opted to downgrade this piece of evidence from the default to 1 point.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/22a56461-b16d-4123-824e-363ce0433447","type":"Finding","dc:description":"\"Depending on when during development the transgene was expressed, the mice showed epilepsy, behavioral hyperactivity, cognitive deficits and/or changes in brain morphology. M-channel-deficient mice showed marked electrophysiological changes in their hippocampal CA1 pyramidal neurons: substantially increased excitability, reduced spike-frequency adaptation, attenuated afterhyperpolarizations (mAHPs) and reduced intrinsic subthreshold theta resonance. Furthermore, these mice had markedly impaired spatial memory in the Morris water maze.\"","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15608631","rdfs:label":"Peters Mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0063ff66-c988-4635-a309-2af473917898_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1119c76c-24d1-439f-a291-7579ff6085cf","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/939dc154-9511-45d8-8b59-43cd06f4ab06","type":"FunctionalAlteration","dc:description":"From the publication: \"We found that the overexpression of the KCNQ2I205V pathogenic variant (Weckhuysen et al., 2012) in wild-type mice, and in a subset of L2/3 pyramidal neurons, exhibited very similar neurophysiological phenotypes to Kcnq2-null neurons. In particular, KCNQ2I205V-expressing neurons produced more APs with faster initial and final firing frequencies than neurons overexpressing KCNQ2 wild-type channels (Fig. 3B).\"","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28100740","rdfs:label":"Niday Functional Alteration"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/69908901-b65a-4a10-8338-535461e39662","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e56bd402-b38c-4d91-9a50-95a75a5b9f28","type":"FunctionalAlteration","dc:description":"Expression of an EE mutation and a BFNS variant at the same residue in CHO cells; current reduction similar with physiologic expression patterns but EE change resulted in mislocalization of the channels.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26007637","rdfs:label":"Abidi Functional Alteration"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/609f91ac-cf3d-4466-91d0-92913707ac5e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c08e8d90-7a16-4b9a-85c6-09886288466d","type":"FunctionalAlteration","dc:description":"These particular variants destabilized the activated voltage sensing domain (VSD) and impeded electrostatic interactions, but reversed with different residue transfection and Retigabine","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23440208","rdfs:label":"Miceli Functional Alteration"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/0063ff66-c988-4635-a309-2af473917898_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f936fa5f-971b-4163-9c0b-46ca5e2595dd","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c0aa3dca-bc5b-4a79-8277-95113646d782","type":"Finding","dc:description":"As discussed in this GeneReviews, it is a well-established fact that KCNQ2 and KCNQ3 dimerize to form a voltage-gated ion channel.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20437616","rdfs:label":"Miceli Biochemical Function","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/a731fdbb-655f-4b6f-abe6-fb9c743c87a2","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/56b9c13c-7512-4416-b9dc-44753d520b82","type":"Finding","dc:description":"While variants in KCNQ3 are not known to cause epileptic encephalopathy, they are known to cause another neonatal-onset epilepsy syndrome, benign familial neonatal seizures.  The ClinGen EIEE working group feels that this is sufficient evidence for biochemical function.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20437616","rdfs:label":"Miceli Interaction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d7235a71-422b-4267-b63b-76c9d2396f40","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b71c9fc6-d84b-4473-918c-f2c6ed9aff40","type":"Finding","dc:description":"Per GTEX, KCNQ2 is predominantly expressed within the brain.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25954001","rdfs:label":"GTEX Expression Data","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/0063ff66-c988-4635-a309-2af473917898_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0063ff66-c988-4635-a309-2af473917898_ad_dn_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/be38adb6-e1da-4eec-8af9-08728a571102_proband_score_evidence_line","type":"EvidenceLine","dc:description":"De novo missense variant without significant supporting experimental evidence - downgrading per Gene Curation WG discussion 8/23/17.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5865e521-4288-487d-b87d-53366cb3abab","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","rdfs:label":"Kato 2013 Individual 14","ageType":"AgeAtReport","ageUnit":"Years","ageValue":8,"detectionMethod":"The authors do not specify which testing modality was used on which patients.  They state \"A total of 239 patients with EOEEs (51 patients with OS, 104 with WS, 4 with EME, and 80 with unclassified epileptic encephalopathy with an age of onset <1 year) were analyzed for KCNQ2 mutations by high-resolution melting (HRM) analysis or WES (30 of 50 patients with OS).\"  As this patient was not originally diagnosed with Ohtahara syndrome, it is likely that they underwent high resolution melting followed by direct sequencing.","phenotypeFreeText":"Original diagnosis was early-onset epileptic encephalopathy, unspecified.  Seizure onset at 2 days of age.  Initial symptoms include facial flushing and eye fixation.  Initial seizure type was tonic, frequency daily.  Initial EEG at 5 days showed multifocal sharp waves.  Subsequent EEGs showed focal spikes with moving loci at each recording.  Seizure-free since 16 months of age.  Moderate intellectual disability; independent sitting achieved at 6 years of age.  Spastic diplegia with dyskinesia.  Athetotic/dystotic movements.","previousTesting":true,"previousTestingDescription":"Per the publication: \"Mutations of STXBP1 or ARX had been excluded in all or male patients in advance, respectively.\"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/be38adb6-e1da-4eec-8af9-08728a571102_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","allele":{"id":"https://genegraph.clinicalgenome.org/r/a7024f9c-7e63-4ddb-8faf-ba22ddc87f68","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_172107.3(KCNQ2):c.794C>T (p.Ala265Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/120176"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/5faea87f-3896-4096-9654-4970b591c346_proband_score_evidence_line","type":"EvidenceLine","dc:description":"De novo missense variant without significant supporting functional evidence - downgrading per Gene Curation WG discussion 8.23.17. However, variant was observed in a single European individual within ExAC (1/65902 European alleles, 1/120382 total alleles).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/60d313ff-08c5-4ee1-970b-3dd42e3907f6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","rdfs:label":"Kato 2013 Individual 304","ageType":"AgeAtReport","ageUnit":"Months","ageValue":22,"detectionMethod":"The authors of this paper do not specify which testing modality was used for their patients with initial diagnoses of Ohtahara syndrome (30/50 received whole exome sequencing, the others received high resolution melting with follow-up direct sequencing of KCNQ2).","phenotypeFreeText":"Initial diagnosis of Ohtahara/West.  Seizure onset at 2-3 days of age (tonic seizures, approximately 10 per day).  Initial EEG at 3 months  showed suppression-burst pattern-like hypsarrhythmia.  Subsequent EEGs showed focal spikes after ACTH.  Other seizure types include partial seizures.  At 22 months of age, patient still has approximately 10 partial seizures per day.  Profound intellectual disability - no head control, no eye tracking.  Authors note that this individual did not have a medical exam until 3 months of age.","previousTesting":true,"previousTestingDescription":"Per the authors: “Mutations of STXBP1... had been excluded in all...patients in advance...”","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/5faea87f-3896-4096-9654-4970b591c346_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","allele":{"id":"https://genegraph.clinicalgenome.org/r/c09719bc-2dfb-4cb2-8532-194bdae86679","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_172107.3(KCNQ2):c.1657C>T (p.Arg553Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/205913"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d226a65f-86bd-4a98-a669-e8126154e269_proband_score_evidence_line","type":"EvidenceLine","dc:description":"De novo missense variant without significant supporting experimental evidence - downgrading per Gene Curation WG discussion 8/23/17.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0346a6ff-f37c-4a78-90c4-806f562ad50d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","rdfs:label":"Kato 2013 Individual 110","ageType":"AgeAtDeath","ageUnit":"Months","ageValue":3,"detectionMethod":"The authors do not specify the testing modality for each individual patient.  Patients with an initial diagnosis of Ohtahara syndrome, such as this one, either underwent whole exome sequencing or high resolution melting (followed by direct sequencing of KCNQ2).","phenotypeFreeText":"Initially diagnosed with Ohtahara syndrome.  Seizure onset at 2 days of age.  Initial symptoms included absent cry, poor suck, stiffening and arching with eye rolling.  Initial seizure type was reported as \"left-sided seizures.\"  Frequency of initial seizures is reported as unknown.  EEG at 5 days of age showed suppression-burst pattern with brief suppression.  Subsequent EEGs showed Rolandic spike waves with normal background activity.  The seizures were intractable despite numerous therapies.  The patient also exhibited hypotonia, jerking of the left arm, stiffening, and arching.  The patient died at 3 months of age.","previousTesting":true,"previousTestingDescription":"Per the authors: \"Mutations of STXBP1 or ARX had been excluded in all or male patients in advance, respectively.\"","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/d226a65f-86bd-4a98-a669-e8126154e269_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","allele":{"id":"https://genegraph.clinicalgenome.org/r/a7024f9c-7e63-4ddb-8faf-ba22ddc87f68"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}},{"id":"https://genegraph.clinicalgenome.org/r/4e849457-289d-44e4-8cf9-28cc73606ad7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","allele":{"id":"https://genegraph.clinicalgenome.org/r/a7024f9c-7e63-4ddb-8faf-ba22ddc87f68"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}]}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/4e849457-289d-44e4-8cf9-28cc73606ad7_proband_score_evidence_line","type":"EvidenceLine","dc:description":"De novo missense variant without significant supporting experimental evidence - downgrading per Gene Curation WG discussion 8/23/17.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0346a6ff-f37c-4a78-90c4-806f562ad50d"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/c1b72496-60e8-48be-93e4-8909852ed25c_proband_score_evidence_line","type":"EvidenceLine","dc:description":"De novo missense variant without significant supporting functional evidence - downgrading per Gene Curation WG discussion 8.23.17.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/90c50cd4-4a94-43fb-9608-f0c23e91682d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22275249","rdfs:label":"Weckhuysen 2012 Individual 4","ageType":"AgeAtReport","ageUnit":"Years","ageValue":5,"detectionMethod":"From publication: \"Genomic DNA was extracted from peripheral blood using standard methods. We Polymerase chain reaction (PCR) amplified the complete coding regions of KCNQ2 and KCNQ3, including exon–intron boundaries, and 50- and 30-untranslated regions (UTRs). PCR products were sequenced using the Big-Dye Terminator Cycle Sequencing kit from Applied Biosystems (Foster City, CA). Sequences were analyzed on an ABI 3730 automated sequencer.\"","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Seizure onset at 3 days of age.  Tonic seizure followed by myoclonic jerks and nystagmus.  Multiple seizures daily at onset.  Initial EEG at 3 days of age showed burst suppression; at 2 months, showed multifocal spikes, spike waves, and sharp waves; at 4 years, showed multifocal spikes, and spike waves increasing during sleep.  Daily tonic seizures despite multidrug regimen at 5.5 years of age.  Profound intellectual disability; nonverbal; spastic quadriplegia; no visual contact.","previousTesting":true,"previousTestingDescription":"Normal karyotype; sequencing for SCN2A, STXBP1.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/c1b72496-60e8-48be-93e4-8909852ed25c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22275249","allele":{"id":"https://genegraph.clinicalgenome.org/r/6a6f3642-2566-4dfe-a5e1-7cee37e338e1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_172107.3(KCNQ2):c.1678C>T (p.Arg560Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/205915"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/ed585f1e-01d0-45ef-b6f5-c16201bca491_proband_score_evidence_line","type":"EvidenceLine","dc:description":"De novo missense variant without significant supporting functional evidence - downgrading per Gene Curation WG discussion 8.23.17.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5153b1d2-edef-472a-806c-1491dddaede6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","rdfs:label":"Kato 2013 Individual 226","ageType":"AgeAtReport","ageUnit":"Years","ageValue":6,"detectionMethod":"The authors of this paper do not specify which testing modality was used for their patients with initial diagnoses of Ohtahara syndrome (30/50 received whole exome sequencing, the others received high resolution melting with follow-up direct sequencing of KCNQ2).","phenotypeFreeText":"Initial diagnosis of Ohtahara syndrome.  Hourly postural tonic seizures starting at 1 day of age.  Initial EEG at 25 days of age showed suppression-burst pattern.  Seizures markedly diminished with phenytoin; seizure-free since 5 years of age.  Profound intellectual disability - no head control, no words.  Spastic quadriplegia.","previousTesting":true,"previousTestingDescription":"Per the authors: “Mutations of STXBP1 or ARX had been excluded in all or male patients in advance, respectively.”","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/ed585f1e-01d0-45ef-b6f5-c16201bca491_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","allele":{"id":"https://genegraph.clinicalgenome.org/r/627f477d-1217-4e6a-9f74-fba1ae1cbc66","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_172107.3(KCNQ2):c.1682C>T (p.Pro561Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/205916"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/eca845d1-d919-4e05-a4c3-f567e1d109dd_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ab5b0cfd-d8fa-48e9-be82-96fb2e664f9d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22275249","rdfs:label":"Weckhuysen 2012 Individual 7","ageType":"AgeAtReport","ageUnit":"Years","ageValue":3,"detectionMethod":"From publication: \"Genomic DNA was extracted from peripheral blood using standard methods. We Polymerase chain reaction (PCR) amplified the complete coding regions of KCNQ2 and KCNQ3, including exon–intron boundaries, and 50- and 30-untranslated regions (UTRs). PCR products were sequenced using the Big-Dye Terminator Cycle Sequencing kit from Applied Biosystems (Foster City, CA).\"","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Seizure onset at day of life 2. Initial seizure type was tonic extension, high-pitched cry, cyanosis, and bradypnea.  Occasional myoclonus of arms.  Multiple seizures daily.  EEG at 5 days showed burst suppression; at 9 days showed multifocal epileptic activity, and was normal at 3 years 11 months.  Despite multiple therapies, still had monthly tonic or tonic clonic seizures, often with fever.  Seizure-free from 11 months to 3 years 2 months (tonic clonic seizure).  Profound intellectual disability; nonverbal; axial hypotonia; walks with assistance; widely-spaced gait.  Nonepileptic aggressive spells.","previousTesting":true,"previousTestingDescription":"History of normal karyotype, sequencing for SCN1A, STXBP1.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/eca845d1-d919-4e05-a4c3-f567e1d109dd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22275249","allele":{"id":"https://genegraph.clinicalgenome.org/r/d52f97d2-b880-4d95-bf6b-9f0c39a42961","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_172107.3(KCNQ2):c.869G>A (p.Gly290Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/39762"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/e2a66893-4167-4ff8-838f-00cf8a62c630_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/800ef4a7-a2f3-453d-9ab0-1873233d50fd","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22275249","rdfs:label":"Weckhuysen 2012 Individual 5","ageType":"AgeAtReport","ageUnit":"Years","ageValue":7,"detectionMethod":"From publication: \"Genomic DNA was extracted from peripheral blood using standard methods. We Polymerase chain reaction (PCR) amplified the complete coding regions of KCNQ2 and KCNQ3, including exon–intron boundaries, and 50- and 30-untranslated regions (UTRs). PCR products were sequenced using the Big-Dye Terminator Cycle Sequencing kit from Applied Biosystems (Foster City, CA). Sequences were analyzed on an ABI 3730 automated sequencer.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Seizure onset at day of life 7.  Initial seizure type was tonic flexion spasms (multiple daily).  EEG at 2 months showed multifocal epileptic activity; at 4 months bilateral temporal sharp waves; and at 3 years slow background with no epileptic activity.  Patient showed a temporary response to vigabatrin, followed by recurrence of extension spasms with nystagmus later in the first year.  Gradual diminishing of seizure frequency thereafter, seizure-free since 2.5 years on combination therapy.  Profound intellectual disability, nonverbal.  Severe spastic quadriplegia with axial hypotonia.","previousTesting":true,"previousTestingDescription":"History of normal cytogenomic microarray, sequencing for MECP2, CDKL5, STXBP1.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/e2a66893-4167-4ff8-838f-00cf8a62c630_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22275249","allele":{"id":"https://genegraph.clinicalgenome.org/r/9bbd623d-4e07-47b4-8a32-0b57fe73dca4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_172107.3(KCNQ2):c.793G>C (p.Ala265Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/369762"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1c1b0488-e473-44e0-8355-a5476d411465_proband_score_evidence_line","type":"EvidenceLine","dc:description":"De novo missense variant without significant supporting experimental evidence - downgrading per Gene Curation WG discussion 8/23/17.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a32a7c75-df81-408c-a2cd-122048c0c77e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","rdfs:label":"Kato 2013 Individual 178","ageType":"AgeAtReport","ageUnit":"Years","ageValue":16,"detectionMethod":"The authors of this paper do not specify which testing modality was used for their patients with initial diagnoses of Ohtahara syndrome (30/50 received whole exome sequencing, the others received high resolution melting with follow-up direct sequencing of KCNQ2).","phenotypeFreeText":"Initially diagnosed with Ohtahara syndrome.  Seizure onset at 2 days of age (tonic).  Frequency of initial seizures was described as \"status.'  Initially EEG at 42 days of age showed suppression burst pattern with brief suppression.  Subsequent EEGs showed multifocal spikes in F4 and T3-5.  Other seizure types observed included partial seizures (eyes rolling up).  Authors do not specify when the patient's seizures were controlled, but does mention that he has only had 1 seizure in the past 10 years.  He has severe intellectual disability, but can speak two-word sentences and walk alone.  Left upper extremity is slightly rigid.  Tooth-grinding noted.","previousTesting":true,"previousTestingDescription":"Per the authors: “Mutations of STXBP1 or ARX had been excluded in all or male patients in advance, respectively.”","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1c1b0488-e473-44e0-8355-a5476d411465_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","allele":{"id":"https://genegraph.clinicalgenome.org/r/00939814-c468-4abf-b9bb-41857ff286fe","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_172107.3(KCNQ2):c.997C>T (p.Arg333Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/21809"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/5437197c-53f2-4617-9fc8-e1cf73ea5c28_proband_score_evidence_line","type":"EvidenceLine","dc:description":"De novo missense variant without significant supporting experimental evidence - downgrading per Gene Curation WG discussion 8/23/17.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/06e5e1d0-3fda-4307-867f-20f3a095f735","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","rdfs:label":"Kato 2013 Individual 232","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"detectionMethod":"\"Genomic DNA was obtained from peripheral blood leukocytes by standard methods, amplified by GenomiPhi version 2 (GE Healthcare, Little Chalfont, United Kingdom), and used for mutation screening. Exons 1–17, covering the entire KCNQ2 coding region (transcript variant 1, NM_172107.2), were examined by HRM analysis or direct sequencing. Samples showing an aberrant melting curve pattern by HRM analysis were sequenced. Polymerase chain reaction (PCR) primers and conditions are available upon request. All novel mutations were verified in the original genomic DNA sample. For the families showing de novo mutations, parentage was confirmed by microsatellite analysis, as previously described (Saitsu et al., 2008). Appropriate biologic parentage was confirmed if three or more informative markers were compatible and the other markers showed no discrepancies.\"","phenotypeFreeText":"Initial diagnosis of early-onset epileptic encephalopathy, unspecified.  Seizure onset at 1 day of age (tonic seizures, 4-5 per hour).  Initial EEG at 58 days of age showed suppression-burst with brief suppression.  Subsequent EEGs showed multifocal spikes.  Seizure-free since two months of age.  Profound intellectual disability.  Walks with support (starting at 3 years of age), but no meaningful words.  History of hypocalcemia as a neonate.","previousTesting":true,"previousTestingDescription":"Per the authors: \"Mutations of STXBP1 or ARX had been excluded in\nall or male patients in advance, respectively.\"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/5437197c-53f2-4617-9fc8-e1cf73ea5c28_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","allele":{"id":"https://genegraph.clinicalgenome.org/r/07e8d2c6-c078-4458-bbb0-9f9ecb5001fd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_172107.3(KCNQ2):c.868G>A (p.Gly290Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/369768"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/8c3f69ad-6fdb-470b-8df9-c6b9b52b16ed_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/74fbc18b-656e-453f-8d25-29d3bcebe1fd","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22275249","rdfs:label":"Weckhuysen 2012 Individual 8","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"detectionMethod":"From publication: \"Genomic DNA was extracted from peripheral blood using standard methods. We Polymerase chain reaction (PCR) amplified the complete coding regions of KCNQ2 and KCNQ3, including exon–intron boundaries, and 50- and 30-untranslated regions (UTRs).\"","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Seizure onset at day of life 2.  Initial seizure type included tonic seizures with version of the head to one side followed by cyanosis and eyelid myoclonias.  Clonic movements left more than right hemicorpus.  Multiple seizures daily.  EEG at 4 weeks showed multifocal epileptic activity most frequently seen in right frontal regions; at 4 months showed slow background and no epileptic activity.  Seizure-free between 2 months and 2 years, 11 months, at which time she had one nocturnal tonic-clonic seizure.  Seizure-free from this point until time of report (4 years, 1 month).  Profound intellectual disability; nonverbal; moderate asymmetric spastic quadriparesis; MRI reported to show thin corpus callosum.","previousTesting":true,"previousTestingDescription":"History of normal karyotype.  Per publication \"Angelman mitochondrial DNA, arylsulfatase A, b-galactosidase\" (no other details available).","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/8c3f69ad-6fdb-470b-8df9-c6b9b52b16ed_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22275249","allele":{"id":"https://genegraph.clinicalgenome.org/r/d52f97d2-b880-4d95-bf6b-9f0c39a42961"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/4198bf3e-a1b1-43d3-8b39-d5097a200a33_proband_score_evidence_line","type":"EvidenceLine","dc:description":"De novo missense variant without significant supporting experimental evidence - downgrading per Gene Curation WG discussion 8/23/17.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/22bea144-4dc2-4d0e-942c-d24afff84b8a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","rdfs:label":"Kato 2013 Individual 205","ageType":"AgeAtReport","ageUnit":"Years","ageValue":2,"detectionMethod":"The authors of this paper do not specify which testing modality (whole exome sequencing [WES] or high resolution melting) they performed on which individuals.  They indicate that some proportion of the individuals originally diagnosed with Ohtahara syndrome (such as this proband) underwent WES, but do not specify which ones.","phenotypeFreeText":"Initially given a clinical diagnosis of Ohtahara syndrome.  Per publication, age of seizure onset was \"0 days.\"  Initial symptoms included paling of the face for several seconds at a time.  Initial seizure type was tonic with eye deviation, multiple times daily.  EEG at 1 day of age showed asymmetric suppression burst; EEG later evolved to diffuse high-amplitude spike and slow waves with multifocal spikes.  Seizure-free after high-dose phenobarbital. At 2 years of age: no head control, non-verbal, social smile.  Profound intellectual disability, spastic quadriplegia.  Myoclonus, opisthotonic posturing.","previousTesting":true,"previousTestingDescription":"Per publication: \"Mutations of STXBP1...excluded in all...patients in advance...\"","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/4198bf3e-a1b1-43d3-8b39-d5097a200a33_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","allele":{"id":"https://genegraph.clinicalgenome.org/r/78882c72-dff4-47c2-a428-4866be675afe","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_172107.3(KCNQ2):c.650C>A (p.Thr217Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/369758"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/fa99ca91-e6fd-469d-ac8b-eb1ab2f19f8f_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/88eae4ff-7aa1-4d19-8757-b25fcafef098","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22275249","rdfs:label":"Weckhuysen 2012 Individual 3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":8,"detectionMethod":"From publication: \"Genomic DNA was extracted from peripheral blood using standard methods. We Polymerase chain reaction (PCR) amplified the complete coding regions of KCNQ2 and KCNQ3, including exon–intron boundaries, and 50- and 30-untranslated regions (UTRs). PCR products were sequenced using the Big-Dye Terminator Cycle Sequencing kit from Applied Biosystems (Foster City, CA). Sequences were analyzed on an ABI 3730 automated sequencer.\"","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Seizure onset day 2 of life.  Mother reports rhythmical jerking similar to seizures during last two months of pregnancy.  Initial seizure type included generalized tonic with tonic components; multiple seizures daily.  EEG at onset showed multifocal epileptic activity most frequencly seen in left temporal and right frontal regions.  Ictal changes showed diffuse attenuation with multifocal spikes (7 days).  Episode of status epilepticus at 3 months.  Seizures controlled with combination therapy; seizure-free from 9 months to 8 years.  Two tonic seizures at 8 years.  Moderate intellectual disability with history of regression following status epilepticus.","previousTesting":true,"previousTestingDescription":"Previous testing included normal karyotype, SCN1A sequencing.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/fa99ca91-e6fd-469d-ac8b-eb1ab2f19f8f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22275249","allele":{"id":"https://genegraph.clinicalgenome.org/r/c74a3f1f-7320-43db-ba86-4e520c9d18ec","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_172107.3(KCNQ2):c.613A>G (p.Ile205Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/369755"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/6bb9ef05-8486-4538-a75f-c785be40c529_proband_score_evidence_line","type":"EvidenceLine","dc:description":"De novo missense variant without significant supporting functional evidence - downgrading per Gene Curation WG discussion 8.23.17.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c1126a25-b9a6-4250-8259-e0e1c07e42a7","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","rdfs:label":"Kato 2013 Individual 17","ageType":"AgeAtReport","ageUnit":"Years","ageValue":24,"detectionMethod":"The authors of this paper do not specify which testing modality was used for their patients with initial diagnoses of Ohtahara syndrome (30/50 received whole exome sequencing, the others received high resolution melting with follow-up direct sequencing of KCNQ2).","phenotypeFreeText":"Initial diagnosis of Ohthara syndrome.  Tonic seizure followed by facial clonic seizure at 3 days of age, greater than 10 per day.  Initial EEG at 4 days showed asymmetric suppression-burst pattern.  Subsequent EEGs showed frontal continuous fast wave and multifocal spikes.  History of tonic seizures or generalized tonic clonic approximately once/week until 10 years of age.  No paroxysms since 10 years of age.  Relapsed at 24 years after a year of drug withdrawal.  Moderate intellectual disability with autistic features.","previousTesting":true,"previousTestingDescription":"Per the authors: “Mutations of STXBP1 or ARX had been excluded in all or male patients in advance, respectively.”","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/6bb9ef05-8486-4538-a75f-c785be40c529_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23621294","allele":{"id":"https://genegraph.clinicalgenome.org/r/f3abd538-61e3-49a7-aac5-384b2cd64fa8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_172107.3(KCNQ2):c.1689C>G (p.Asp563Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/369806"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/567f0933-8c5f-416c-a5d0-8122a78f916a_proband_score_evidence_line","type":"EvidenceLine","dc:description":"De novo missense variant without significant supporting functional evidence - downgrading per Gene Curation WG discussion 8.23.17.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b2e432e3-eb8c-414e-b610-d4818facbef9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22275249","rdfs:label":"Weckhuysen 2012 Individual 6","ageType":"AgeAtReport","ageUnit":"Years","ageValue":9,"detectionMethod":"From publication: \"Genomic DNA was extracted from peripheral blood using standard methods. We Polymerase chain reaction (PCR) amplified the complete coding regions of KCNQ2 and KCNQ3, including exon–intron boundaries, and 50- and 30-untranslated regions (UTRs). PCR products were sequenced using the Big-Dye Terminator Cycle Sequencing kit from Applied Biosystems (Foster City, CA). Sequences were analyzed on an ABI 3730 automated sequencer.\"","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Seizure onset at 3 days of age.  Initial seizure type was tonic extension with clonic movements, left hemicorpus, and eyelid myoclonia.  Multiple seizures daily.  EEG at 3 days of age showed burst suppression; at 3 weeks of age showed multifocal epileptic activity, and was normal at 8 years of age.  Despite multiple therapies, patient still had daily tonic seizures, often lateralized to the left.  After 2 months, the seizures evolved to sporadic tonic seizures with carbamazepine and vigabatrin.  Seizure-free since 3 years of age, maintained  with carbamazepine.  Profound intellectual disability, nonverbal, widely-spaced gait, mild spasticity.  Plagiocephaly, large forehead, large mouth, and widely-spaced teeth.  Hypospadias.  Autism with stereotypic hand movements.","previousTesting":true,"previousTestingDescription":"History of normal karyotype, sequencing of SCN1A, SCN2A, STXBP1, Angelman testing (methodology not specified).","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/567f0933-8c5f-416c-a5d0-8122a78f916a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22275249","allele":{"id":"https://genegraph.clinicalgenome.org/r/f46bf9e0-69e7-47be-9c0b-7aedd525addc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_172107.3(KCNQ2):c.1636A>G (p.Met546Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/39761"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallAutosomalDominantDeNovoVariantEvidenceCriteria","strengthScore":12}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":216,"specifiedBy":"GeneValidityCriteria5","strengthScore":16,"subject":{"id":"https://genegraph.clinicalgenome.org/r/cdVdeCIWml8","type":"GeneValidityProposition","disease":"obo:MONDO_0018614","gene":"hgnc:6296","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_0063ff66-c988-4635-a309-2af473917898-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}